NSE: TORNTPHARM | BSE: 500420

Expensive Star

Download real time

4018.20 14.50 (0.36%)

Near 52W High of ₹4104.80

174.4K NSE+BSE Volume

NSE 16 Jan, 2026 3:31 PM (IST)

135,994.1

Market Cap

High in industry

Beta 1Year

Very Low volatility

Torrent Pharmaceuticals Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for TORNTPHARM, BSE:500420 Torrent Pharmaceuticals Ltd.

Search Inside the pdf :

Torrent Pharmaceuticals Ltd.

12 Dec 2025

4018.20

0.36%

Committed towards a healthier tomorrow

Buy: Torrent Pharmaceuticals Ltd.

FundsIndia

Branded generics in India and Brazil contribute 73% of revenue. Chronic and sub-chronic therapies form 76% of India sales.

Torrent Pharma has gained 26.41% in the last 1 Year

Torrent Pharmaceuticals Ltd.

10 Nov 2025

4018.20

0.36%

Torrent Pharmaceuticals (TRP IN) Q2FY26 Result Update BGx...

Accumulate: Torrent Pharmaceuticals Ltd.

Target

Prabhudas Lilladhar

Number of FII/FPI investors increased from 892 to 905 in Dec 2025 qtr.

Torrent Pharmaceuticals Ltd.

10 Nov 2025

4018.20

0.36%

BP Equities Q2FY26 Result Update Torrent Pharmaceuticals Ltd.

Results Update: Torrent Pharmaceuticals Ltd.

BP Wealth

...

Number of FII/FPI investors increased from 892 to 905 in Dec 2025 qtr.

Torrent Pharmaceuticals Ltd.

09 Nov 2025

4018.20

0.36%

Branded generics gaining scale

Hold: Torrent Pharmaceuticals Ltd.

ICICI Securities Limited

Torrent Pharma’s (Torrent) Q2FY26 result was in line with our expectations. While Torrent continues to grow at a faster pace in India (+11.5%), its growth in the US (+15.9%) was driven by new launches like gEntresto; stability in currency has sustained its growth in Brazil (+20.9%).

Number of FII/FPI investors increased from 892 to 905 in Dec 2025 qtr.

Torrent Pharmaceuticals Ltd.

08 Nov 2025

4018.20

0.36%

Execution gains in DF/LATAM/US

Neutral: Torrent Pharmaceuticals Ltd.

Target

Motilal Oswal

Torrent Pharma (TRP) delivered in-line financial performance for the quarter. YoY growth improved in the US generics and LATAM markets, led by new product launches and steady market share gains in the base portfolio.

Torrent Pharmaceuticals Ltd. is trading above all available SMAs

Torrent Pharmaceuticals Ltd.

09 Oct 2025

4018.20

0.36%

TORRENT PHARMA

Hold: Torrent Pharmaceuticals Ltd.

Recommendation Target

Geojit BNP Paribas

Revenue from the Indian market grew 10.8% YoY to Rs. 1,811cr, led by outperformance in focus therapies. The US market's revenue grew 18.9% YoY to Rs. 308cr, as recent launches achieved the targeted market shares. Market revenue from Brazil rose 11.2% YoY to Rs. 218cr, driven by top brands and the performance of...

Number of FII/FPI investors increased from 892 to 905 in Dec 2025 qtr.

Torrent Pharmaceuticals Ltd.

29 Aug 2025

4018.20

0.36%

Strong domestic player, Acquisitions hold key to growth

Buy: Torrent Pharmaceuticals Ltd.

Target

Sharekhan

Company’s India portfolio clocked a 13% CAGR in the past 5 years; its momentum is expected to continue led by the chronic portfolio and recent acquisition of JB Chemicals.

Number of FII/FPI investors increased from 892 to 905 in Dec 2025 qtr.

Torrent Pharmaceuticals Ltd.

29 Jul 2025

4018.20

0.36%

Branded biz growth robust; margin outlook unchanged

Hold: Torrent Pharmaceuticals Ltd.

Target

ICICI Securities Limited

Torrent Pharma’s (Torrent) Q1FY26 results were slightly below our expectations. Addition of MRs and price hikes continue to fuel growth in India (+10.8% YoY).

Torrent Pharmaceuticals Ltd. is trading above all available SMAs

Torrent Pharmaceuticals Ltd.

29 Jul 2025

4018.20

0.36%

Torrent Pharmaceuticals (TRP IN) Q1FY26 Result Update Strong...

Accumulate: Torrent Pharmaceuticals Ltd.

Target

Prabhudas Lilladhar

Torrent Pharma's (TRP) Q1FY26 adjusted EBITDA was broadly in line with our estimates. Our FY26/ FY27E EBITDA broadly remain unchanged. TRP reported Rs 90bn (80% of total sales) worth of highly profitable branded formulation sales spread across India, Brazil and RoW markets. The acquisition of JB Chemicals & Pharma (JBCP) appears strategically compelling, making it the 5th largest player in the domestic pharma market. This will further be strengthening its position in high-margin chronic therapies and opens up many...

Torrent Pharma has gained 26.41% in the last 1 Year

Is Torrent Pharmaceuticals Ltd. worth buying?

160 Votes:

Buy 73.75%

Sell 16.88%

Hold 9.38%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Results Update SEE REPORTS >

pdf